Investigational drug · Phase 2
Pempulimab
Not approved by FDA. In 1 industry-sponsored Phase 2 or 3 trial that is active or finished in the last two years, most often for Nasopharyngeal Carcinoma.
Phase 2Last checked: Nov 19, 2026Latest source record: Apr 7, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 2
Industry-sponsored trials
Phase 2 and 3 trials
1
0 still active
All registered trials
1
Any phase or sponsor naming "Pempulimab"
First trial start
2022
Oct 27, 2022
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "Pempulimab", any sponsor or status.
Conditions studied
As listed on its trial records.
- Nasopharyngeal Carcinoma
Approved drugs for the same conditions: Oncology
Largest trials
Live from ClinicalTrials.gov: studies naming "Pempulimab" as an intervention, largest first.
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.Industry
NCT05563480 · 47 participants · Start Oct 27, 2022 · Primary completion May 28, 2025
Drug: TQB2618 Injection, Pempulimab Injection, Cisplatin Injection, Gemcitabine Hydrochloride Injection; TQB2618 injection; Penpulimab injection · For: Nasopharyngeal Carcinoma
Sites: Guangzhou, China; Zhuhai, China; Nanning, China · 5 sites in all
Newest research
PubMed records naming it or its code names, newest first.
No PubMed records name it yet, which is common for early code-named drugs.
Also in development for Nasopharyngeal Carcinoma
- BMS-986507BL-B01D1, Iza-brenPhase 351 trials
Sichuan Baili Pharmaceutical Co., Ltd. · Non-small Cell Lung Cancer, Solid Tumor, Urothelial Carcinoma
- YL201Tambotatug Pelitecan, Tam-PeliPhase 311 trials
MediLink Therapeutics (Suzhou) Co., Ltd. · Advanced Solid Tumor, Small Cell Lung Cancer, Metastatic Pancreatic Cancer
- PD-1 monoclonal antibodyPhase 39 trials
Sichuan Baili Pharmaceutical Co., Ltd. · Nasopharyngeal Carcinoma (NPC), Non-small Cell Lung Cancer, Nasopharyngeal Carcinoma
- KL-A167Phase 34 trials
Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. · Non-small Cell Lung Cancer, Nasopharyngeal Carcinoma, Recurrent or Metastatic
- SI-B003Phase 210 trials
Sichuan Baili Pharmaceutical Co., Ltd. · Non-small Cell Lung Cancer, Head and Neck Squamous Cell Carcinoma, Squamous Cell Carcinoma of Head and Neck
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.